Aimmune Therapeutics’ Phase II trial completion shifted AR201’s Phase Transition Success Rate (PTSR) by 9 points to 11%, as of 21 June. Aimmune is a Nestle Health Science company, following its acquisition by the latter in August 2020.

The Phase II trial (NCT04056299), which is evaluating the oral desensitisation therapy regimen AR201 in people with a hen-egg allergy, was completed as per an 18 June update on the trial’s entry. The first patient on this study was enrolled in mid-2019, as per a 21 August press release. AR201 is based on the company’s platform Characterised Oral Desensitisation ImmunoTherapy (CODIT) platform which involves desensitising patients with defined amounts of key allergens, thereby providing a meaningful level of protection against allergic reactions. Aimmune has an approval for its peanut allergy immunotherapy Palforzia, based on the same CODIT platform, under its belt.

The Phase II trial’s primary endpoint is measuring efficacy assessed by the highest tolerated dose of at least 1,000mg dried egg white protein given in a double-blind, placebo-controlled food challenge. While the trial is completed, study results have not yet been posted.

PTSR is the probability, given as a percentage, of a drug progressing successfully from one development stage to the next. The PTSR score considers characteristics like therapy area, indication and molecule type, and is used to calculate a drug’s Likelihood of Approval (LoA), which in this case is 8% following a seven-point increase after the trial update.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.